Compared with generic drugs, the development of innovative chemical drugs is more difficult, expensive, and time-consuming. Innovative chemical drug R&D in China has long been dominated by research institutes. In the past ten plus years, foreign chemical innovative drugs have shown good curative effect and economic benefits in the market, and they have received more and more attention. As these drugs have entered the domestic market, they have further stimulated domestic pharmaceutical companies, and more and more companies have begun to increase the research and development of innovative chemical drugs.
In recent years, pharmaceutical companies’ investment in innovative chemical drug R&D has continued to increase, from 4.652 billion yuan in 2013 to 18.473 billion yuan in 2018, with a five-year growth rate of nearly four times.
Also subscribe to our CRO newsletter to receive current development, events, and reports like this from our industry:
CR Medicon (https://en.crmedicon.com) provides innovative pharma and biotech companies with comprehensive clinical development services, including drug registration, medical affairs, clinical operations, data management & statistical analysis, and biological sample analysis. We are China’s most well-known clinical CRO partner, for both domestic and overseas companies. CR Medicon team consists more than 200 full-time employees with clinical sites in both USA and China. Contact us at +1 (732) 624-9052 or email email@example.com.